Status:
COMPLETED
Allergic Rhinitis Changes the Sinus Microbiome
Lead Sponsor:
University of Chicago
Conditions:
Seasonal Allergic Rhinitis
Eligibility:
All Genders
18-55 years
Phase:
PHASE4
Brief Summary
The investigators hypothesize that treatment with QNASL will reduce nasal mucosal inflammation induced by the allergy season and prevent the changes in the microbiome caused by the allergy season.
Eligibility Criteria
Inclusion
- Males and females between 18 and 55 years of age.
- Two year history of seasonal allergic rhinitis.
- Positive skin test to grass and/or tree antigen.
Exclusion
- Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.
- Pregnant or lactating women.
- Subjects treated with systemic steroids during the previous 30 days.
- Subjects treated with topical (inhaled, intranasal or intraocular) steroids, Nasalcrom or Opticrom during the previous 30 days.
- Subjects treated with oral antihistamine/decongestants during the previous seven days.
- Subjects treated with topical (intranasal or intraocular) antihistamine/decongestants during the previous 3 days.
- Subjects treated with immunotherapy and are escalating their dose.
- Subjects on chronic anti-asthma medications.
- Subjects with polyps in the nose or a significantly displaced septum.
- Upper respiratory infection within 14 days prior to study start.
Key Trial Info
Start Date :
January 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT01852513
Start Date
January 1 2013
End Date
June 1 2014
Last Update
October 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Chicago
Chicago, Illinois, United States, 60637